SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.69 CNY | +0.59% |
|
-0.80% | -6.23% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,262 | 4,776 | 12,093 | 14,085 | 10,391 | 9,632 |
| Enterprise Value (EV) 1 | 3,917 | 4,569 | 11,976 | 14,075 | 10,372 | 9,632 |
| P/E ratio | -44.5 x | 75.3 x | -61.7 x | 52 x | -706 x | -29 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.41 x | 8.41 x | 43.7 x | 35 x | 29.1 x | 22.4 x |
| EV / Revenue | 5.89 x | 8.05 x | 43.3 x | 34.9 x | 29 x | 22.4 x |
| EV / EBITDA | 74.3 x | -86 x | -59.7 x | -97.5 x | -93.8 x | -98 x |
| EV / FCF | -6.47 x | 11.4 x | -1,856 x | 7,692 x | 121 x | - |
| FCF Yield | -15.5% | 8.8% | -0.05% | 0.01% | 0.83% | - |
| Price to Book | 1.54 x | 2.07 x | 5.71 x | 5.9 x | 4.38 x | - |
| Nbr of stocks (in thousands) | 6,59,736 | 6,59,736 | 6,59,736 | 6,59,736 | 6,59,736 | 6,59,736 |
| Reference price 2 | 6.460 | 7.240 | 18.33 | 21.35 | 15.75 | 14.60 |
| Announcement Date | 24/04/19 | 23/06/20 | 28/04/21 | 29/04/22 | 26/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 664.6 | 567.6 | 276.8 | 402.7 | 357.1 | 429.8 |
| EBITDA 1 | 52.69 | -53.16 | -200.7 | -144.4 | -110.6 | -98.28 |
| EBIT 1 | -6.555 | -111.2 | -260.3 | -203.9 | -175.6 | -166.7 |
| Operating Margin | -0.99% | -19.58% | -94.04% | -50.64% | -49.17% | -38.78% |
| Earnings before Tax (EBT) 1 | -83.18 | 76.77 | -201.8 | 278.6 | 12.72 | -313.2 |
| Net income 1 | -95.79 | 63.38 | -195.9 | 271 | -14.69 | -332.5 |
| Net margin | -14.41% | 11.17% | -70.78% | 67.29% | -4.11% | -77.35% |
| EPS 2 | -0.1452 | 0.0961 | -0.2970 | 0.4108 | -0.0223 | -0.5039 |
| Free Cash Flow 1 | -605.5 | 402.1 | -6.454 | 1.83 | 85.69 | - |
| FCF margin | -91.11% | 70.84% | -2.33% | 0.45% | 24% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 634.39% | - | 0.68% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 24/04/19 | 23/06/20 | 28/04/21 | 29/04/22 | 26/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 345 | 207 | 117 | 10.6 | 18.5 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -606 | 402 | -6.45 | 1.83 | 85.7 | - |
| ROE (net income / shareholders' equity) | -3.22% | 2.8% | -8.66% | 12% | -0.04% | - |
| ROA (Net income/ Total Assets) | -0.1% | -1.8% | -5.55% | -4.9% | -3.91% | - |
| Assets 1 | 97,051 | -3,522 | 3,528 | -5,529 | 375.8 | - |
| Book Value Per Share 2 | 4.190 | 3.500 | 3.210 | 3.620 | 3.600 | - |
| Cash Flow per Share 2 | 2.340 | 1.700 | 0.4300 | 0.2800 | 0.2800 | - |
| Capex 1 | 608 | 36.3 | 67.7 | 60.8 | 31.5 | 4.32 |
| Capex / Sales | 91.52% | 6.39% | 24.45% | 15.11% | 8.81% | 1% |
| Announcement Date | 24/04/19 | 23/06/20 | 28/04/21 | 29/04/22 | 26/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.23% | 1.24B | |
| -3.35% | 88.91B | |
| +2.76% | 41.25B | |
| -13.92% | 31.99B | |
| +50.51% | 24.73B | |
| -15.25% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.80% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- 002581 Stock
- Financials Shandong Sinobioway Biomedicine Co., Ltd.